secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001641489-24-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics FY2023 net loss $20.3M; $51M PIPE funds Phase 3 cadisegliatin trial
--------------------------------------------------------------------------------

- Net loss attributable to shareholders $20.3M ($9.71/share) in FY2023 vs $19.2M ($9.98) in FY2022.
- Cash $9.4M at Dec 31, 2023; subsequent $51M PIPE from institutional investors and JDRF T1D Fund closed Feb 28, 2024.
- First Phase 3 trial of cadisegliatin for type 1 diabetes to enroll first patient in Q2 2024; top-line data expected by Q1 2026.
- R&D expenses $13.6M in FY2023 (up 10% YoY); G&A expenses $11.9M (down 2% YoY).
- Board reduced from 9 to 7; three new directors designated by new investors including Srinivas Akkaraju from Samsara.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/0001641489-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/vtvt-20240313.htm
  HTML page:      https://secwatch.observer/filing/0001641489-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer